Literature DB >> 10644484

Clostridium difficile toxin: cytoskeletal changes and lactate dehydrogenase release in hepatocytes.

E M Grossmann1, W E Longo, D L Kaminski, G S Smith, C E Murphy, R L Durham, M J Shapiro, J G Norman, J E Mazuski.   

Abstract

BACKGROUND: We have found that Clostridium difficile toxins can evoke hepatocyte acute-phase protein synthesis, and that this effect is dependent on a functioning interleukin-1 (IL-1) receptor. The present study was undertaken to determine if C. difficile toxicity, as determined by actin rearrangement and lactate dehydrogenase (LDH) release, also requires a functioning IL-1 receptor.
METHODS: Primary hepatocyte cultures were prepared from normal mice, knockout mice deficient in the IL-1-converting enzyme (ICE), and knockout mice deficient in the IL-1 p80 receptor. Hepatocytes were treated for 24 h with C. difficile culture extract, purified C. difficile toxin A, or purified C. difficile toxin B. The actin cytoskeleton was examined using confocal microscopy, and LDH release was measured by spectrophotometric analysis.
RESULTS: C. difficile culture extract, toxin A, and toxin B induced collapse of the actin cytoskeleton in hepatocytes from normal mice. Hepatocytes from both the ICE-deficient mice and the IL-1 p80 receptor-deficient mice demonstrated similar responses to both toxins. These toxins also induced significant LDH release in a concentration-dependent fashion in the normal hepatocytes and the ICE-deficient hepatocytes. However, no significant increase in LDH release was observed in hepatocytes from IL-1 p80 receptor-deficient mice.
CONCLUSIONS: C. difficile toxins induce actin cytoskeletal collapse independent of IL-1 or the IL-1 receptor. In contrast, toxin-stimulated LDH release was dependent on the presence of the IL-1 receptor. Thus, separate pathways appear to mediate toxic effects as manifested by actin rearrangement and LDH release. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10644484     DOI: 10.1006/jsre.1999.5736

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  6 in total

Review 1.  Clostridium difficile infection in the intensive care unit.

Authors:  David J Riddle; Erik R Dubberke
Journal:  Infect Dis Clin North Am       Date:  2009-09       Impact factor: 5.982

2.  Recombinant single-chain variable fragment antibodies directed against Clostridium difficile toxin B produced by use of an optimized phage display system.

Authors:  Xiao K Deng; Lance A Nesbit; K John Morrow
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

3.  High temporal resolution of glucosyltransferase dependent and independent effects of Clostridium difficile toxins across multiple cell types.

Authors:  Kevin M D'Auria; Meghan J Bloom; Yesenia Reyes; Mary C Gray; Edward J van Opstal; Jason A Papin; Erik L Hewlett
Journal:  BMC Microbiol       Date:  2015-02-04       Impact factor: 3.605

4.  Identification of toxemia in patients with Clostridium difficile infection.

Authors:  Hua Yu; Kevin Chen; Jianguo Wu; Zhiyong Yang; Lianfa Shi; Lydia L Barlow; David M Aronoff; Kevin W Garey; Tor C Savidge; Erik C von Rosenvinge; Ciaran P Kelly; Hanping Feng
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

5.  Biophysical Characterization and Activity of Lymphostatin, a Multifunctional Virulence Factor of Attaching and Effacing Escherichia coli.

Authors:  Robin L Cassady-Cain; Elizabeth A Blackburn; Husam Alsarraf; Emil Dedic; Andrew G Bease; Bettina Böttcher; René Jørgensen; Martin Wear; Mark P Stevens
Journal:  J Biol Chem       Date:  2016-01-19       Impact factor: 5.157

6.  The Vacuolating Autotransporter Toxin (Vat) of Escherichia coli Causes Cell Cytoskeleton Changes and Produces Non-lysosomal Vacuole Formation in Bladder Epithelial Cells.

Authors:  Juan Manuel Díaz; Charles M Dozois; Francisco Javier Avelar-González; Eduardo Hernández-Cuellar; Pravil Pokharel; Alfredo Salazar de Santiago; Alma Lilian Guerrero-Barrera
Journal:  Front Cell Infect Microbiol       Date:  2020-06-26       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.